Efficacy and Safety of Pelubiprofen for Primary Dysmenorrhea: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Two-Period Crossover Trial
Journal of Clinical Medicine · 31.03.2026 · 15 (7) · 2658
DOI: 10.3390/jcm15072658 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 31.03.2026. Verfasst von Joo Hyun Park und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Yongin Severance Hospital, Yonsei University College of Medicine, Yongin 16995, Republic of Korea. Die Arbeit nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Daewon Pharmaceutical, Daewon Pharmaceutical Co., Ltd. https://ror.org/05j0gfp71.
Abstract (Originalsprache)
Background
Primary dysmenorrhea is a common gynecologic condition that frequently requires pharmacologic treatment. Pelubiprofen, a 2-arylpropionic acid-derived prodrug with relatively selective cyclooxygenase-2 inhibitory activity, has demonstrated analgesic efficacy in acute pain conditions.
Methods
This multicenter, randomized, double-blind, placebo-controlled, crossover phase 3 trial randomized 120 women aged 19–44 years with primary dysmenorrhea to one of two treatment sequences over two menstrual cycles. Pelubiprofen at 45 mg or a matching placebo was administered at the onset of moderate or severe menstrual pain. The co-primary endpoints were time-weighted sums of the total pain relief (TOTPAR-8) and pain intensity difference (SPID-8) during the first 8 h after dosing.
Results
Of 120 randomized women, 115 comprised the modified intention-to-treat population and 116 comprised the safety population. Pelubiprofen demonstrated significantly greater analgesic efficacy than placebo, with least-squares mean TOTPAR-8 values of 22.17 versus 15.50 and SPID-8 values of 10.00 versus 6.17 (both p < 0.0001). Significant between-treatment differences were also observed at 12 h (TOTPAR-12 and SPID-12). Treatment-emergent adverse events occurred in 9/113 (8.0%) pelubiprofen treatment periods and 10/112 (8.9%) placebo treatment periods; all events were mild to moderate, and the only serious adverse event occurred during a placebo treatment period and was judged to be unrelated to study treatment.
Conclusions
Pelubiprofen at 45 mg provided superior short-term analgesic efficacy compared with placebo and was generally well tolerated in women with primary dysmenorrhea.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Obstetrics and Gynecology, Yongin Severance Hospital, Yonsei University College of Medicine, Yongin 16995, Republic of Korea.
- Institute of Women's Life Medical Science, Yonsei University College of Medicine, Seoul 03722, Republic of Korea.
- Department of Obstetrics and Gynecology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul 06273, Republic of Korea.
- Department of Obstetrics and Gynecology, Inha University Hospital, College of Medicine, Inha University, Incheon 22332, Republic of Korea.
- Department of Obstetrics and Gynecology, Chungbuk National University Hospital, Cheongju 28644, Republic of Korea.
- Department of Obstetrics and Gynecology, Biomedical Research Institute, Pusan National University Hospital, Pusan National University School of Medicine, Busan 49241, Republic of Korea.
ORCID-Profile: Joo Hyun Park, Sung Pil Choo, Jae-Hoon Lee, Jong Kil Joo, Hyun Tae Park, Sang Ho Yoon, Jung Ryeol Lee, SiHyun Cho, Young Sik Choi
Förderung
- Daewon Pharmaceutical
- Daewon Pharmaceutical Co., Ltd. https://ror.org/05j0gfp71
Zitieren
APA
Park, J. H., Lee, I., Choo, S. P., Lee, J. H., Hong, S. H., Joo, J. K., Park, H. T., Kim, M. R., Lee, D. Y., Yi, K. W., Yoon, S. H., Shin, J. H., Lee, J. R., Kim, S. H., Cho, S., & Choi, Y. S. (2026). Efficacy and Safety of Pelubiprofen for Primary Dysmenorrhea: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Two-Period Crossover Trial. Journal of Clinical Medicine, 15(7), 2658. https://doi.org/10.3390/jcm15072658
Vancouver
Park JH, Lee I, Choo SP, Lee JH, Hong SH, Joo JK, et al. Efficacy and Safety of Pelubiprofen for Primary Dysmenorrhea: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Two-Period Crossover Trial. Journal of Clinical Medicine. 2026;15(7):2658. doi:10.3390/jcm15072658
BibTeX
@article{Park2026,
author = {Park, Joo Hyun and Lee, Inha and Choo, Sung Pil and Lee, Jae-Hoon and Hong, Seung Hwa and Joo, Jong Kil and Park, Hyun Tae and Kim, Mi Ran and Lee, Dong-Yun and Yi, Kyong Wook and Yoon, Sang Ho and Shin, Jung-Ho and Lee, Jung Ryeol and Kim, Sung Hoon and Cho, SiHyun and Choi, Young Sik},
title = {Efficacy and Safety of Pelubiprofen for Primary Dysmenorrhea: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Two-Period Crossover Trial},
journal = {Journal of Clinical Medicine},
year = {2026},
volume = {15},
number = {7},
pages = {2658},
doi = {10.3390/jcm15072658}
}
EUVIMED